ArticleInternational journal of clinical oncology2022

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).

Yukari Tsubata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.